254 related articles for article (PubMed ID: 32282866)
1. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
Wagner SM; Melchardt T; Greil R
Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
[TBL] [Abstract][Full Text] [Related]
2. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á; Pinczés LI; Egyed M
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
Qin A
Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
[No Abstract] [Full Text] [Related]
6. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
[TBL] [Abstract][Full Text] [Related]
7. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
[TBL] [Abstract][Full Text] [Related]
8. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
9. Ropeginterferon alfa-2 b for the therapy of polycythemia vera.
Červinek L
Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868
[TBL] [Abstract][Full Text] [Related]
10. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
[TBL] [Abstract][Full Text] [Related]
12. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
[TBL] [Abstract][Full Text] [Related]
14. Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera.
Krecak I; Skelin M; Verstovsek S
Expert Rev Hematol; 2023 May; 16(5):305-316. PubMed ID: 37002907
[TBL] [Abstract][Full Text] [Related]
15. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
Huang YW; Hsu CW; Lu SN; Yu ML; Su CW; Su WW; Chien RN; Hsu CS; Hsu SJ; Lai HC; Qin A; Tseng KC; Chen PJ
Hepatol Int; 2020 Dec; 14(6):997-1008. PubMed ID: 33099752
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic approaches in polycythemia vera.
Foucar CE; Stein BL
Clin Adv Hematol Oncol; 2018 Nov; 16(11):750-757. PubMed ID: 30543590
[TBL] [Abstract][Full Text] [Related]
17. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
Huang YW; Qin A; Tsai CY; Chen PJ
Viruses; 2022 May; 14(6):. PubMed ID: 35746606
[TBL] [Abstract][Full Text] [Related]
18. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
[TBL] [Abstract][Full Text] [Related]
20. Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P; Mascarenhas J; Bose P; Hobbs G; Yacoub A; Palmer JM; Gerds AT; Masarova L; Kuykendall AT; Rampal RK; Mesa R; Verstovsek S
Ther Adv Hematol; 2024; 15():20406207241229588. PubMed ID: 38380373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]